Pfizer Spins Off Esperion While Retaining Former Subsidiary’s Top Compounds
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer retains undisclosed stake in Esperion, which will focus on small-molecule dyslipidemia candidate.